StockSelector.com
  Research, Select, & Monitor Saturday, August 24, 2019 1:48:58 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Rubius Therapeutics$9.60($.58)(5.70%)

  Quote | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

Rubius Therapeutics has an overall rank of 3422 out of 7130 stocks based on 6 positive rankings and 7 negative rankings.

Positive Rankings
Target Prices
The average analysts' target price is $40.00 for Rubius Therapeutics using target prices set or adjusted within the past 90 days. Among companies with recent target prices and with the average above the current stock price, Rubius Therapeutics is ranked 16.
Oversold Stochastics
Rubius Therapeutics rank is 249
Oversold RSI
The 14 Day Relative-Strength Index for Rubius Therapeutics is 27.4. An RSI below 30 indicates the stock is oversold. Among companies with a low RSI, Rubius Therapeutics is ranked 335.
Low vPut/Call
Rubius Therapeutics has a low Put/Call ratio of 0.21 on active options expiring within the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Rubius Therapeutics is ranked 431.
Debt-to-Equity
Rubius Therapeutics rank is 501
Low Put/Call
Rubius Therapeutics has a low Put/Call ratio of 0.21 on all open interest of options expiring in the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Rubius Therapeutics is ranked 563.
Negative Rankings
10 Day Loss
Rubius Therapeutics rank is 281
90 Day Loss
Rubius Therapeutics rank is 421
Down EPS Surprise
Rubius Therapeutics missed the consensus earnings estimate when it last reported quarterly earnings.
Down Ratings Revision
During the past month, the average analyst's rating or recommendation has decreased. Among companies that have been downgraded within the past month, Rubius Therapeutics is ranked 592.
Negative ROE
Rubius Therapeutics rank is 927
Negative ROA
Rubius Therapeutics rank is 955
Price-to-Book
Rubius Therapeutics rank is 2140







Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2019 StockSelector.com. All rights reserved.